Skip to main content
HR 1003 118th Congress House Armed Forces and National Security

VA Medicinal Cannabis Research Act of 2023

Introduced: July 9, 2024 Introduced by: Correa, J. Luis Democratic · California See on congress.gov
This bill died when the 118th Congress ended
It never became law before the 118th Congress (2023–2024) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Mar 13, 2023
Referred to the Subcommittee on Health.
Feb 14, 2023
Introduced in House
Feb 14, 2023
Referred to the House Committee on Veterans' Affairs.
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

VA Medicinal Cannabis Research Act of 2023

This bill requires the Department of Veterans Affairs (VA) to study the effects of cannabis on veterans who are enrolled in the VA health care system and have been diagnosed with post-traumatic stress disorder (PTSD) or chronic pain (i.e., eligible veterans).

First, the bill requires the VA to conduct an observational, 18-month study on the effects of cannabis on the health outcomes of eligible veterans. The VA must report on the study and address whether it is able to meet criteria necessary to conduct clinical trials.

Then, if the VA determines that it is able to proceed, it must carry out a series of clinical trials on the effects of cannabis appropriate for investigational use, as determined by the Food and Drug Administration, on the outcomes of eligible veterans. The VA must carry out a long-term observational study of the clinical trial participants.

The VA may terminate the trials if it is unable to meet clinical guideline requirements or the trials would create excessive risk to participants.

The VA must ensure that the study and trials are representative of the demographics of veterans in the United States, as determined by the most recent data from the American Community Survey of the Bureau of the Census.

The study and trials must include mechanisms to ensure data preservation and registration as necessary (in an anonymous form).

What's happening now March 13, 2023

Referred to the Subcommittee on Health.

 Related & companion bills 1
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 2
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 1003: VA Medicinal Cannabis Research Act of 2023. 118th Congress. Open America. https://openamerica.io/bill/118-HR-1003/
MLA
"H.R. 1003: VA Medicinal Cannabis Research Act of 2023." 118th Congress, 2026, Open America, https://openamerica.io/bill/118-HR-1003/.
Bluebook (legal)
H.R. 1003, 118th Cong. (2026), https://openamerica.io/bill/118-HR-1003/.
Markdown link
[H.R. 1003: VA Medicinal Cannabis Research Act of 2023](https://openamerica.io/bill/118-HR-1003/)
Report a problem